Valuation dashboard for Arcellx, Inc. (ACLX) with P/E N/A, P/B 16.10, EV/EBITDA N/A and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM).
Analysis Summary
Trailing-twelve-month margins: gross margin -64.8%, operating margin -11.4%, net margin -10.3%.
Balance sheet quality for ACLX: current ratio of 4.4. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 16.10 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $0.84 |
| vs Current Price | -99.3% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ACLX | Arcellx, Inc. | $6.7B | 16.10 | ||
| ARWR | Arrowhead Pharmaceuticals, Inc. | $9.3B | 19.78 | -0.3% | |
| PCVX | Vaxcyte, Inc. | $8.5B | 3.10 | -37.6% | |
| KYMR | Kymera Therapeutics, Inc. | $9.6B | 7.56 | ||
| ALKS | Alkermes plc | $7.7B | 112.07 | 4.16 | |
| IMVT | Immunovant, Inc. | $7.5B | 9.99 | ||
| CRSP | CRISPR Therapeutics AG | $5.0B | 2.86 | ||
| NAMS | NewAmsterdam Pharma Company N.V. | $2.5B | 5.45 | -29.8% |
Price
| Price | $115.07 |
| Market Cap | $6.7B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Gross Margin | -64.81% |
| Operating Margin | -1135.61% |
| Net Margin | -1027.25% |
Related companies: AKRO · ALKS · ARWR · CRSP · IMVT · KYMR · NAMS
Explore sector: Healthcare · Biotechnology
More sections of ACLX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks